Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akari TherapeuticsSTU:CLA1 30 Peter Lynch Fair Value is €172.33 as of Aug. 25, 2026. GuruFocus rates STU:CLA1 with a GF Score™ of 30/100. Among 66 Biotechnology companies, Akari Therapeutics ranks better than 96.97% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Akari Therapeutics's PEG is 1. Akari Therapeutics's 5-Year TTM EBITDA Growth Rate is 25.
Akari Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was €6.89. Therefore, the Peter Lynch Fair Value for today is €172.33.
The historical rank and industry rank for Akari Therapeutics's Peter Lynch Fair Value or its related term are showing as below:
STU:CLA1'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.03 Med: 0.1 Max: 0.83
Current: 0.04
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Akari Therapeutics was 0.83. The lowest was 0.03. And the median was 0.10.
STU:CLA1's Price-to-Peter-Lynch-Fair-Value is ranked better than 96.97% of 66
companies
in the Biotechnology industry
Industry Median: 1.245
vs STU:CLA1: 0.04
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Akari Therapeutics (STU:CLA1) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.
Akari Therapeutics's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
134.40
/
172.33
=
0.78
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akari Therapeutics Peter Lynch Fair Value Related Terms
Akari Therapeutics Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Akari Therapeutics's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:CLA1 vs MBRX, INTI, TPST: Peter Lynch Fair Value Comparison
For the Biotechnology subindustry, Akari Therapeutics's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akari Therapeutics Price-to-Peter-Lynch-Fair-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Akari Therapeutics's Price-to-Peter-Lynch-Fair-Value falls into.
Akari Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.89.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of €172.33 mean?
Akari Therapeutics (STU:CLA1) has a Peter Lynch Fair Value of €172.33 as of Aug. 25, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Akari Therapeutics and its competitors. According to the industry distribution chart, Akari Therapeutics ranks #2 out of 66 companies in the Biotechnology industry, placing it in the top 3%.
Is Akari Therapeutics' Peter Lynch Fair Value too high?
Akari Therapeutics' current Peter Lynch Fair Value is €172.33. Based on the distribution chart, Akari Therapeutics ranks #2 out of 66 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Akari Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Akari Therapeutics' Peter Lynch Fair Value compare to MBRX and INTI?
According to the Biotechnology industry distribution chart, Akari Therapeutics ranks #2 out of 66 companies for Peter Lynch Fair Value. This places Akari Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median Peter Lynch Fair Value is 1.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Biotechnology company?
The median Peter Lynch Fair Value among Biotechnology companies is 1.25, based on 66 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Akari Therapeutics and its competitors. For the Biotechnology industry, the median Peter Lynch Fair Value is 1.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akari Therapeutics's current Peter Lynch Fair Value is €172.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akari Therapeutics stock overvalued right now?
Akari Therapeutics (STU:CLA1) has a current Peter Lynch Fair Value of €172.33. The current Peter Lynch Fair Value is €172.33. Akari Therapeutics' overall GF Score™ is 30/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Akari Therapeutics (STU:CLA1), the current Peter Lynch Fair Value is €172.33 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
30GF Score
Get the complete analysis for STU:CLA1
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CLA1 has been successfully added to your 
